Mammary Cell News Volume 3.42 | Oct 27 2011

Estrogen Induces Apoptosis in Estrogen Deprivation-Resistant Breast Cancer through Stress Responses As Identified by Global Gene Expression Across Time
Scientists interrogated 17β-estradiol (E₂)-induced apoptosis by analysis of gene expression across time (2–96 hours) in MCF-7 cell variants that were estrogen-dependent or resistant to estrogen deprivation and refractory or sensitive to E₂-induced apoptosis. [Proc Natl Acad Sci USA] Abstract

Selectin Ligand Sialyl-Lewis X Antigen Drives Metastasis of Hormone-Dependent Breast Cancers
Investigators found that genes involved in the synthesis of sialyl-Lewis x (FUT3, FUT4 and ST3GAL6) are significantly increased in estrogen receptor (ER) alpha negative tumors compared to ER-positive ones. [Cancer Res] Abstract

TGFβ1 Inhibition Increases the Radiosensitivity of Breast Cancer Cells In Vitro and Promotes Tumor Control by Radiation In Vivo
The purpose of this study is to determine whether inhibition of TGFβ signaling prior to irradiation sensitizes human and murine cancer cells in vitro and in vivo. [Clin Cancer Res] Abstract

TIEG1 Inhibits Breast Cancer Invasion and Metastasis by Inhibition of EGFR Transcription and the EGFR Signaling Pathway
In this study, scientists find that decreased TIEG1 expression is associated with increased EGFR expression in breast cancer tissues and cell lines. [Mol Cell Biol] Abstract

CLINICAL RESEARCH

Assessment of Letrozole and Tamoxifen Alone and In Sequence for Postmenopausal Women with Steroid Hormone Receptor-Positive Breast Cancer: The BIG 1-98 Randomized Clinical Trial at 8·1 Years Median Follow-Up
Investigators present an update of efficacy outcomes in the Breast International Group (BIG) 1-98 study at 8·1 years median follow-up. [Lancet Oncol] Abstract | Press Release

Capecitabine Versus Classical Cyclophosphamide, Methotrexate, and Fluorouracil As First-Line Chemotherapy for Advanced Breast Cancer
Scientists compared oral capecitabine, administered intermittently or continuously, versus classical cyclophosphamide, methotrexate, and fluorouracil as first-line chemotherapy for women with advanced breast cancer unsuited to more intensive regimens. [J Clin Oncol] Abstract

Dasatinib as a Single Agent in Triple-Negative Breast Cancer: Results of an Open-Label Phase II Study
This phase II trial assessed efficacy and safety of single-agent dasatinib in patients with advanced triple-negative breast cancer. [Clin Cancer Res] Abstract

The Combined Influence of Multiple Sex and Growth Hormones on Risk of Postmenopausal Breast Cancer: A Nested Case-Control Study
Investigators considered the role of estrone, estradiol, estrone sulfate, testosterone, androstenedione, dehydroepiandrosterone (DHEA), DHEA sulfate, and prolactin, and secondarily insulin-like growth factor and c-peptide, in postmenopausal breast cancer risk, among 265 cases and 541 controls in the prospective Nurses’ Health Study. [Breast Cancer Res] Abstract | Press Release

Preclinical and Clinical Evaluation of Intraductally Administered Agents in Early Breast Cancer
Researchers performed preclinical studies in N-methyl-N′-nitrosourea–treated rats to compare the effects of 5-fluorouracil, carboplatin, nanoparticle albumin-bound paclitaxel, and methotrexate to the previously reported efficacy of pegylated liposomal doxorubicin (PLD) on treatment of early and established mammary tumors. Concurrently, they initiated a clinical trial to establish the feasibility, safety, and maximum tolerated dose of intraductal PLD. [Sci Transl Med] Abstract | Press Release

Ohio State Dedicates Comprehensive Breast Center in Honor of Stefanie Spielman
The Ohio State University President E. Gordon Gee announced the naming of The Stefanie Spielman Comprehensive Breast Center, in honor of the Ohio State alumna, philanthropist and advocate. [The James Comprehensive Cancer Center] Press Release

Cracking Breast Cancer’s Genetic Code May Lead to New Treatments
Michigan State University’s Eran Andrechek, an assistant professor in the Department of Physiology, has received a $450,000 grant from the Susan G. Komen for the Cure foundation to better understand the differences both within and between breast cancers. [Michigan State University] Press Release

Sheffield Launches New Cancer Research Center
Cancer Research UK and Yorkshire Cancer Research have come together for the first time to fund a new cancer research center in Sheffield. [Cancer Research UK] Press Release

National Institutes of Health (United States)

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)

Visit our events page to see a complete list of events in the mammary cell community.

Lab Technologist – Tissue Culture (STEMCELL Technologies)

Research and Development Technologist, hPSC Media (STEMCELL Technologies)

Scientist (iPSC) (STEMCELL Technologies)

Contract Assay Service Technologist (STEMCELL Technologies)

Lab Technologist – Pluripotent Stem Cells (STEMCELL Technologies)

Quality Control Technologist – Cell Separation (STEMCELL Technologies)

Scientist – Pluripotent Stem Cells (STEMCELL Technologies)

Postdoctoral Fellow in Breast Cancer (Indiana University School of Medicine)

Research Fellow in Breast Cancer Research (Monash University)

Postdoctoral Fellow in Breast Cancer (Indiana University School of Medicine)

Recruit Top Talent

Reach more than 11,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Jobs are categorized regionally: United States, Canada, Europe, Asia Pacific

Visit here to post your career opportunities.

Have we missed an important article or publication in Mammary Cell News? Click here to submit!

Comments or Suggestions? Email info@connexoncreative.com with your feedback.